Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar;21(3):273-283.
doi: 10.1016/S1474-4422(21)00359-8.

Management of atherosclerotic extracranial carotid artery stenosis

Affiliations
Review

Management of atherosclerotic extracranial carotid artery stenosis

Leo H Bonati et al. Lancet Neurol. 2022 Mar.

Abstract

Atherosclerosis leading to stenosis of the internal carotid artery is the underlying cause of 8-15% of ischaemic strokes (symptomatic carotid stenosis). 1-2% of the adult population have asymptomatic carotid stenosis. Clinical trials in patients with symptomatic carotid stenosis showed a higher procedural risk of non-disabling stroke with stenting versus endarterectomy, but a higher risk of myocardial infarction, cranial nerve palsy, and access site haematoma with endarterectomy. Apart from procedural complications, both treatments are equally effective in preventing stroke and recurrent severe carotid stenosis in the medium-to-long term. Endarterectomy has a modest effect in preventing stroke among patients with asymptomatic carotid stenosis, whereas the role of stenting remains to be established. With advances in medical therapy against atherosclerosis, benefit from invasive therapy has become uncertain. Risk modelling, with the inclusion of brain and carotid plaque imaging, will become increasingly important in selecting patients for interventions.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests LHB has received grants from Swiss National Science Foundation, University of Basel, Swiss Heart Foundation, and AstraZeneca; personal fees from Amgen, Bayer, Bristol-Myers Squibb, Claret Medical, and InnovHeart; and non-financial support from AstraZeneca and Bayer. OJ has received personal fees from Acandis. The other authors declare no competing interests.

Comment in

  • Imaging of the carotid artery.
    Evans NR, Rudd JHF, Warburton EA. Evans NR, et al. Lancet Neurol. 2022 Jul;21(7):588. doi: 10.1016/S1474-4422(22)00223-X. Lancet Neurol. 2022. PMID: 35716685 No abstract available.
  • Imaging of the carotid artery - Authors' reply.
    Brown MM, Bonati LH. Brown MM, et al. Lancet Neurol. 2022 Jul;21(7):588-589. doi: 10.1016/S1474-4422(22)00224-1. Lancet Neurol. 2022. PMID: 35716686 No abstract available.

Publication types

LinkOut - more resources